A-Disintegrin and Metalloprotease (ADAM) 10 and 17 promote self-renewal of brain tumor sphere forming cells

Cancer Letters

Volumn 326, Issue 1, 2012, Pages 79-87

  Bulstrode, Harry ^a,b   Jones, Louise M ^a   Siney, Elodie J ^a   Sampson, Jessica M ^a   Ludwig, Andreas ^c   Gray, William P ^a   Willaime Morawek, Sandrine ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

ADAM10; ADAM17; Brain tumor

Indexed keywords

ADAM10 ENDOPEPTIDASE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ADULT; ARTICLE; BRAIN TUMOR SPHERE FORMING CELL; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CELL DEATH; CELL PROLIFERATION; CELL RENEWAL; CLINICAL ARTICLE; CONTROLLED STUDY; DEPLETION; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; NERVE CELL DIFFERENTIATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR DIFFERENTIATION;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; BRAIN NEOPLASMS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; GLIOMA; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; NEOPLASTIC STEM CELLS; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED;

EID: 84866184063     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.022     Document Type: Article

References (44)

1. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
2. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., Williams P.M., Modrusan Z., Feuerstein B.G., Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
3. Zaidi H.A., Kosztowski T., DiMeco F., Quinones-Hinojosa A. Origins and clinical implications of the brain tumor stem cell hypothesis. J. Neurooncol. 2009, 93:49-60.
4. Hide T., Takezaki T., Nakamura H., Kuratsu J., Kondo T. Brain tumor stem cells as research and treatment targets. Brain Tumor Pathol. 2008, 25:67-72.
5. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Aspects Med. 2008, 29:258-289.
6. Rubio-Araiz A., Arevalo-Martin A., Gomez-Torres O., Navarro-Galve B., Garcia-Ovejero D., Suetterlin P., Sanchez-Heras E., Molina-Holgado E., Molina-Holgado F. The endocannabinoid system modulates a transient TNF pathway that induces neural stem cell proliferation. Mol. Cell Neurosci. 2008, 38:374-380.
7. Jorissen E., Prox J., Bernreuther C., Weber S., Schwanbeck R., Serneels L., Snellinx A., Craessaerts K., Thathiah A., Tesseur I., Bartsch U., Weskamp G., Blobel C.P., Glatzel M., De Strooper B., Saftig P. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J. Neurosci. 2010, 30:4833-4844.
8. Zheng X., Jiang F., Katakowski M., Zhang Z.G., Lu Q.E., Chopp M. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation. Cancer Biol. Ther. 2009, 8:1045-1054.
9. Pruessmeyer J., Ludwig A. The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin Cell Dev. Biol. 2009, 20:164-174.
10. Alexson T.O., Hitoshi S., Coles B.L., Bernstein A., van der Kooy D. Notch signaling is required to maintain all neural stem cell populations-irrespective of spatial or temporal niche. Dev. Neurosci. 2006, 28:34-48.
11. van Tetering G., van Diest P., Verlaan I., van der Wall E., Kopan R., Vooijs M. Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J. Biol. Chem. 2009, 284:31018-31027.
12. Pan D., Rubin G.M. Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during drosophila and vertebrate neurogenesis. Cell 1997, 90:271-280.
13. Bozkulak E.C., Weinmaster G. Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol. Cell Biol. 2009, 29:5679-5695.
14. Brou C., Logeat F., Gupta N., Bessia C., LeBail O., Doedens J.R., Cumano A., Roux P., Black R.A., Israel A. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 2000, 5:207-216.
15. van Goor H., Melenhorst W.B., Turner A.J., Holgate S.T. Adamalysins in biology and disease. J. Pathol. 2009, 219:277-286.
16. Kohutek Z.A., diPierro C.G., Redpath G.T., Hussaini I.M. ADAM-10-mediated N-cadherin cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell migration. J. Neurosci. 2009, 29:4605-4615.
17. Weskamp G., Mendelson K., Swendeman S., Le Gall S., Ma Y., Lyman S., Hinoki A., Eguchi S., Guaiquil V., Horiuchi K., Blobel C.P. Pathological neovascularization is reduced by inactivation of ADAM17 in endothelial cells but not in pericytes. Circ. Res. 2010, 106:932-940.
18. Zheng X., Jiang F., Katakowski M., Kalkanis S.N., Hong X., Zhang X., Zhang Z.G., Yang H., Chopp M. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 2007, 98:674-684.
19. Zheng ., Jiang F., Katakowski M., Lu Y., Chopp M. ADAM17 promotes glioma cell malignant phenotype. Mol. Carcinog. 2011.
20. Lu Y., Jiang F., Zheng X., Katakowski M., Buller B., To S.S., Chopp M. TGF-beta1 promotes motility and invasiveness of glioma cells through activation of ADAM17. Oncol. Rep. 2011, 25:1329-1335.
21. Kodama T., Ikeda E., Okada A., Ohtsuka T., Shimoda M., Shiomi T., Yoshida K., Nakada M., Ohuchi E., Okada Y. ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor. Am. J. Pathol. 2004, 165:1743-1753.
22. Wildeboer D., My Sang Q.X., Bartsch J.W., Pagenstecher A. Metalloproteinase disintegrins ADAM8 and ADAM19 are highly regulated in human primary brain tumors and their expression levels and activities are associated with invasiveness. J. Neuropathol. Exp. Neurol. 2006, 65:516-527.
23. Duffy M.J., McKiernan E., O'Donovan N., McGowan P.M. Role of ADAMs in cancer formation and progression. Clin. Cancer Res. 2009, 15:1140-1144.
24. Katakowski M., Jiang F., Zheng X., Gutierrez J.A., Szalad A., Chopp M. Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Sci. 2009, 100:1597-1604.
25. M. Gijsen, P. King, T. Perera, P. Parker, B. Larijani, A. Harris, A. Kong, Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer, in, Breast Cancer Res., 2010, pp. O2.
26. M. Lenkiewicz, N. Li, S.K. Singh, Culture and Isolation of Brain Tumor Initiating Cells, 2009.
27. Hundhausen C., Misztela D., Berkhout T.A., Broadway N., Saftig P., Reiss K., Hartmann D., Fahrenholz F., Postina R., Matthews V., Kallen K.J., Rose-John S., Ludwig A. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood 2003, 102:1186-1195.
28. Ludwig A., Hundhausen C., Lambert M.H., Broadway N., Andrews R.C., Bickett D.M., Leesnitzer M.A., Becherer J.D. Metalloproteinase inhibitors for the disintegrin-like metalloproteinases ADAM10 and ADAM17 that differentially block constitutive and phorbol ester-inducible shedding of cell surface molecules. Comb. Chem. High Throughput. Screen. 2005, 8:161-171.
29. Lenkiewicz M., Li N., Singh S.K. Culture and isolation of brain tumor initiating cells. Curr. Protoc. Stem Cell Biol. 2009, 1:Unit 3.3. (Chapter 3).
30. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
31. Fael Al-Mayhani T.M., Ball S.L., Zhao J.W., Fawcett J., Ichimura K., Collins P.V., Watts C. An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J. Neurosci. Methods 2009, 176:192-199.
32. Arima T., Enokida H., Kubo H., Kagara I., Matsuda R., Toki K., Nishimura H., Chiyomaru T., Tatarano S., Idesako T., Nishiyama K., Nakagawa M. Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Sci. 2007, 98:1720-1726.
33. Gutwein P., Schramme A., Sinke N., Abdel-Bakky M.S., Voss B., Obermuller N., Doberstein K., Koziolek M., Fritzsche F., Johannsen M., Jung K., Schaider H., Altevogt P., Ludwig A., Pfeilschifter J., Kristiansen G. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur. J. Cancer 2009, 45:478-489.
34. Kenchappa R.S., Tep C., Korade Z., Urra S., Bronfman F.C., Yoon S.O., Carter B.D. P75 neurotrophin receptor-mediated apoptosis in sympathetic neurons involves a biphasic activation of JNK and up-regulation of tumor necrosis factor-alpha-converting enzyme/ADAM17. J. Biol. Chem. 2010, 285:20358-20368.
35. Kuhn P.H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J.W., Kremmer E., Rossner S., Lichtenthaler S.F. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO. J. 2010, 29:3020-3032.
36. Slack B.E., Ma L.K., Seah C.C. Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme. Biochem. J. 2001, 357:787-794.
37. Gooz M. ADAM-17: the enzyme that does it all. Crit. Rev. Biochem. Mol. Biol. 2010, 45:146-169.
38. N.C. Institute, Rembrandt Database, in: N.C. Institute (Ed.), 2005. http://caintegrator-info.nci.nih.gov/rembrandt.
39. Tropepe V., Sibilia M., Ciruna B.G., Rossant J., Wagner E.F., van der Kooy D. Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev. Biol. 1999, 208:166-188.
40. Maretzky T., Schulte M., Ludwig A., Rose-John S., Blobel C., Hartmann D., Altevogt P., Saftig P., Reiss K. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol. Cell Biol. 2005, 25:9040-9053.
41. Gooz P., Gooz M., Baldys A., Hoffman S. ADAM-17 regulates endothelial cell morphology, proliferation, and in vitro angiogenesis. Biochem. Biophys. Res. Commun. 2009, 380:33-38.
42. Moss M.L., Stoeck A., Yan W., Dempsey P.J. ADAM10 as a target for anti-cancer therapy. Curr. Pharm. Biotechnol. 2008, 9:2-8.
43. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., Alexe G., Lawrence M., O'Kelly M., Tamayo P., Weir B.A., Gabriel S., Winckler W., Gupta S., Jakkula L., Feiler H.S., Hodgson J.G., James C.D., Sarkaria J.N., Brennan C., Kahn A., Spellman P.T., Wilson R.K., Speed T.P., Gray J.W., Meyerson M., Getz G., Perou C.M., Hayes D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
44. Wu Y., Cain-Hom C., Choy L., Hagenbeek T.J., de Leon G.P., Chen Y., Finkle D., Venook R., Wu X., Ridgway J., Schahin-Reed D., Dow G.J., Shelton A., Stawicki S., Watts R.J., Zhang J., Choy R., Howard P., Kadyk L., Yan M., Zha J., Callahan C.A., Hymowitz S.G., Siebel C.W. Therapeutic antibody targeting of individual Notch receptors. Nature 2010, 464:1052-1057.